X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (42) 42
male (40) 40
index medicus (39) 39
female (38) 38
aged (35) 35
middle aged (33) 33
oncology (33) 33
colorectal cancer (25) 25
cancer (20) 20
metastasis (20) 20
colorectal neoplasms - drug therapy (18) 18
patients (17) 17
adult (16) 16
chemotherapy (16) 16
treatment outcome (16) 16
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
metastases (14) 14
survival (14) 14
research (13) 13
bevacizumab (12) 12
colorectal carcinoma (12) 12
colorectal neoplasms - pathology (12) 12
oxaliplatin (12) 12
prognosis (12) 12
analysis (11) 11
camptothecin - analogs & derivatives (10) 10
clinical trials (10) 10
colorectal neoplasms - genetics (10) 10
disease-free survival (10) 10
fluorouracil (10) 10
drug therapy (9) 9
irinotecan (9) 9
retrospective studies (9) 9
studies (9) 9
tumors (9) 9
care and treatment (8) 8
colorectal neoplasms - mortality (8) 8
fluorouracil - administration & dosage (8) 8
genetic aspects (8) 8
leucovorin (8) 8
mutation (8) 8
neoplasm metastasis (8) 8
single-nucleotide polymorphism (8) 8
1st-line treatment (7) 7
5-fluorouracil (7) 7
abridged index medicus (7) 7
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
diagnosis (7) 7
health aspects (7) 7
hematology, oncology and palliative medicine (7) 7
leucovorin - administration & dosage (7) 7
medical research (7) 7
medicine, general & internal (7) 7
risk factors (7) 7
survival analysis (7) 7
therapy (7) 7
adenocarcinoma - drug therapy (6) 6
camptothecin - administration & dosage (6) 6
cancer patients (6) 6
cancer therapies (6) 6
cetuximab (6) 6
expression (6) 6
kaplan-meier estimate (6) 6
neoplasm staging (6) 6
polymorphism, single nucleotide (6) 6
single nucleotide polymorphisms (6) 6
surgery (6) 6
trial (6) 6
usage (6) 6
adenocarcinoma - mortality (5) 5
article (5) 5
biomarkers (5) 5
biomarkers, tumor - genetics (5) 5
camptothecin - therapeutic use (5) 5
cells (5) 5
deoxyribonucleic acid--dna (5) 5
dosage and administration (5) 5
drug administration schedule (5) 5
fluorouracil - therapeutic use (5) 5
follow-up studies (5) 5
genotype (5) 5
leucovorin - therapeutic use (5) 5
medical prognosis (5) 5
organoplatinum compounds - administration & dosage (5) 5
research article (5) 5
risk (5) 5
toxicity (5) 5
vascular endothelial growth factor (5) 5
adenocarcinoma (4) 4
adenocarcinoma - pathology (4) 4
alleles (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal, humanized (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - therapeutic use (4) 4
apoptosis (4) 4
bevacizumab - administration & dosage (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 9, pp. 845 - 852
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 937 - 948
Summary Background Tumour mutational status is an important determinant of the response of metastatic colorectal cancer to targeted treatments. However, the... 
Hematology, Oncology and Palliative Medicine | KRAS MUTATIONS | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | RANDOMIZED PHASE-III | INHIBITS GROWTH | ACQUIRED-RESISTANCE | FLUOROURACIL | PLACEBO PLUS | TUMOR-GROWTH | Predictive Value of Tests | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Clinical Trials, Phase III as Topic | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Real-Time Polymerase Chain Reaction | Precision Medicine | Receptor, TIE-1 - blood | Phosphatidylinositol 3-Kinases - blood | Genetic Predisposition to Disease | Adenocarcinoma - blood | ras Proteins - blood | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Disease Progression | Phenotype | Class I Phosphatidylinositol 3-Kinases | Biomarkers, Tumor - genetics | ras Proteins - genetics | Patient Selection | DNA, Neoplasm - blood | Female | Adenocarcinoma - genetics | Retrospective Studies | Pyridines - therapeutic use | Colorectal Neoplasms - mortality | Colorectal Neoplasms - blood | Kaplan-Meier Estimate | Proportional Hazards Models | Phenylurea Compounds - therapeutic use | Proto-Oncogene Proteins B-raf - blood | Proto-Oncogene Proteins - genetics | Treatment Outcome | Randomized Controlled Trials as Topic | Biomarkers, Tumor - blood | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Proto-Oncogene Proteins B-raf - genetics | Aged | DNA, Neoplasm - genetics | Colorectal Neoplasms - pathology | Proto-Oncogene Proteins - blood | Adenocarcinoma - mortality | Medical colleges | Medical research | Cancer patients | Prognosis | Liver | DNA | Colorectal cancer | Genetic research | Medicine, Experimental | Metastasis
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. 1709 - 1719
Journal Article
JAMA - Journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
Journal Article
Journal Article
by Shitara, Kohei and Özgüroğlu, Mustafa and Bang, Yung-Jue and Di Bartolomeo, Maria and Mandalà, Mario and Ryu, Min-Hee and Fornaro, Lorenzo and Olesiński, Tomasz and Caglevic, Christian and Chung, Hyun C and Chung, Hyun Cheol and Muro, Kei and Goekkurt, Eray and Mansoor, Wasat and McDermott, Raymond S and Shacham-Shmueli, Einat and Chen, Xinqun and Chen, Jen-Shi and Mayo, Carlos and Kang, S Peter and Ohtsu, Atsushi and Fuchs, Charles S and Lerzo, Guillermo and O'Connor, Juan Manuel and Mendez, Guillermo Ariel and Lynam, James and Tebbutt, Niall and Wong, Mark and Strickland, Andrew and Karapetis, Chris and Goldstein, David and Vasey, Paul and Van Laethem, Jean-Luc and Van Cutsem, Eric and Berry, Scott and Vincent, Mark and Muller, Bettina and Rey, Felipe and Zambrano, Angela and Guerra, Joaquin and Krogh, Merete and Baeksgaard, Lene and Yilmaz, Mette and Elme, Anneli and Magi, Andrus and Auvinen, Paivi and Alanko, Tuomo and Moehler, Markus and Kunzmann, Volker and Seufferlein, Thomas and Thuss-Patience, Peter and Hoehler, Thomas and Haag, Georg and Al-Batran, Salah-Eddin and Castro, Hugo and Lopez, Karla and Aguilar Vasquez, Mynor and Sandoval, Mario and Lam, Ka On and Cuffe, Sinead and Kelly, Cathy and Geva, Ravit and Hubert, Ayala and Beny, Alex and Brenner, Baruch and Giuseppe, Aprile and Falcone, Alfredo and Maiello, Evaristo and Passalacqua, Rodolfo and Montesarchio, Vincenzo and Hara, Hiroki and Chin, Keisho and Nishina, Tomohiro and Komatsu, Yoshito and Machida, Nozumo and Hironaka, Shuichi and Satoh, Taroh and Tamura, Takao and Sugimoto, Naotaoshi and Cho, Haruhiko and Omuro, Yashushi and Kato, Ken and Goto, Masahiro and Hyodo, Ichinosuke and Yoshida, Kazuhiro and Baba, Hideo and Esaki, Taito and Furuse, Junji and Wan Mohammed, Wan Zamaniah and Hernandez Hernandez, Carlos and Casas Garcia, Juan and Dominguez Andrade, Adriana and Clarke, Katriona and Hjortland, Geir and Glenjen, Nils and Kubiatowski, Tomasz and Jacek, Jassem and Wojtukiewicz, Marek and Lazarev, Sergey and Lancukhay, Yuri and ... and KEYNOTE-061 Investigators and KEYNOTE-061 investigators
The Lancet, ISSN 0140-6736, 07/2018, Volume 392, Issue 10142, pp. 123 - 133
Journal Article
Journal Article